Posted by Michael Wonder on 08 Jan 2026
Vera Therapeutics announces US FDA granted priority review to biologics license application for atacicept for treatment of adults with IgA nephropathy
7 January 2026 - Vera Therapeutics today announced the atacicept biologics license application for the treatment of adults with immunoglobulin A nephropathy was accepted for priority review by the US FDA.
The biologics license application, which was submitted using the accelerated approval program, was assigned a PDUFA target action date of 7 July 2026.
